Your Article Summary
See Latest ArticlesRelative effectiveness of osteoporosis drugs for preventing nonvertebral fracture
Annals of Internal Medicine, 05/09/08
Cadarette SM et al. - Differences in fracture risk between risedronate or raloxifene and alendronate were small. Nasal calcitonin recipients may have a higher risk for nonvertebral fractures compared with alendronate recipients.
Methods- Aim was to compare the relative effectiveness of osteoporosis treatments to reduce nonvertebral fracture risk among older adults
- 43,135 new recipients of oral bisphosphonates, nasal calcitonin, and raloxifene
- The mean age was 79 yrs, and 96% were women
- The primary outcome was nonvertebral fracture within 12 mos of treatment initiation
- Alendronate was the reference category in all analyses
- A total of 1051 nonvertebral fractures were observed within 12 mos
- No large differences in fracture risk were found between risedronate or raloxifene and alendronate
- Among those with a fracture history, raloxifene recipients experienced more nonvertebral fractures within 12 mos vs alendronate recipients
- Pts who received calcitonin experienced more nonvertebral fractures than those who received alendronate
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Haematologica, 12/08/09
Review: aspirin reduces vascular events but increases bleeding in primary and secondary prevention
Evidence-Based Medicine, 12/08/09
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09